Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297203 | 1.00 | ALDH1A1 (0.63) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL4291123 | 0.91 | ALDH1A1 (0.66) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL4291128 | 0.91 | ALDH1A1 (0.66) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL4298441 | 0.82 | ALDH1A1 (0.70) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL4298444 | 0.82 | ALDH1A1 (0.70) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL4296045 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL4296048 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL5308812 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL532793 | 0.77 | GAA (0.71) | ALDH1A1MAPTPKMLMNAGAA | |
| SCHEMBL31189953 | 0.74 | ALDH1A1 (0.69) | ALDH1A1MAPTPKMLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | ALDH1A1 2708/4885MAPT 4442/4885PKM 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.